Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315)

HKG:2315 Revenue

Biocytogen Pharmaceuticals (Beijing) had revenue of 433.06M CNY in the quarter ending March 31, 2026, with 39.48% growth. This brings the company's revenue in the last twelve months to 1.56B, up 43.92% year-over-year. In the year 2025, Biocytogen Pharmaceuticals (Beijing) had annual revenue of 1.38B with 40.63% growth.

• Revenue (ttm): 1.56B CNY
• Revenue Growth: +43.92%
• P/S Ratio: 23.93
• Revenue / Employee: 1.08M CNY
• Employees: 1,443
• Market Cap: 42.51B HKD

Revenue Chart

* This company reports financials in CNY.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	1.38B	398.35M	40.63%
Dec 31, 2024	980.45M	263.54M	36.76%
Dec 31, 2023	716.91M	183.03M	34.28%
Dec 31, 2022	533.88M	179.33M	50.58%
Dec 31, 2021	354.56M	101.01M	39.84%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

May 3, 2026

Data Sources Report a data error